TB vaccine study for people with drug-sensitive lung tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental vaccine (ID93 + GLA-SE) given alongside standard tuberculosis (TB) treatment. It aims to see if the vaccine can improve the body's response to TB treatment and reduce the chance of TB coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active TB in your lungs that is confirmed to be sensitive to rifampicin (a common TB drug).
- You are either HIV-negative or, if HIV-positive, you have been on HIV treatment for at least 90 days and have a CD4 count of 250 or higher.
- You have not been treated for TB before (this is your first time).
- You are currently on or about to start standard TB treatment (within a specific time window).
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use contraception during the study.
- You do not have certain medical conditions like severe autoimmune disease, uncontrolled diabetes, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new tuberculosis (TB) vaccine (ID93+GLA-SE) in healthy adults aged 55 to 74. It aims to see if the vaccine is safe and can help protect against TB, especially in people who may have latent (inactive) TB infection.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial studies whether atorvastatin (a cholesterol medicine) can reduce ongoing inflammation after you finish standard tuberculosis (TB) treatment. If it works, it may improve how your body recovers after TB, especially by lowering inflammation-related signals.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.